article · Scientific Reports
Antimicrobial therapy is a primary approach for treating microbial infections, yet increasing antibiotic resistance continues to hinder effective disease management, highlighting natural products as promising alternative sources of novel anti-infective agents. In this context, Citrus medica cv. ‘rugosa’ EO was chemically profiled by GC-MS, and its antimicrobial, antibiofilm, and anti-quorum sensing inhibitory action was firstly tested using both in vitro and computational studies. C. medica cv ‘‘rugosa ‘’ EO revealed a predominance of monoterpene hydrocarbons (79.12%) with limonene (76.15%) as the major component, along with minor compounds such as limonene oxide (3.32%), trans-carvyl acetate (1.93%), nerol (1.75%), cis-carveol (1.37%), myrcene (1.31%), carvacrol (1.14%), and β-bisabolene (1.10%). The EO exhibited potent broad-spectrum antimicrobial activity, with inhibition zones up to 30.00 ± 1.73 mm, surpassing limonene (6.00–25.00 mm) and ampicillin (6.00–8.67 mm), and antifungal effects (12.33–14.33 mm) comparable to amphotericin B (11.67–15.33 mm). MICs values ranged from 0.097–1.562 mg/mL with MBC/MFC ratios mostly 2–8, indicating strong bactericidal and fungicidal activity. The EO also demonstrated dose-dependent antibiofilm inhibition (B. subtilis 84.57%; P. aeruginosa 43.19%), quorum-sensing suppression in C. violaceum (100% at MIC; 62.70% at MIC/2; 34.78% at MIC/4) and reduced swarming motility (77.17–46.74%), highlighting its anti-virulence potential. Computational analyses of C. medica cv. ‘rugosa’ EO phytocompounds, particularly valencene (− 9.3 kcal/mol) and aromadendrene (− 8.3 kcal/mol), showed strong binding affinities and stable 200 ns MD interactions, along with favorable ADMET profiles, confirming their drug-like potential. These results indicate that phytochemicals from these medicinal plants possess promising anti-infective and anti-virulence properties and merit further investigation for therapeutic applications.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1038/s41598-026-47009-4
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.